Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00206258 · ClinicalTrials.gov registry record · Phase 3
The Role of Amylin and Glucagon in T1DM
A Phase 3 study, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00206258 is a Phase 3 study that has completed, run by Baylor College of Medicine. The registered enrollment target is 30 participants.
The verdict
NCT00206258, a Phase 3 study, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
The purpose of this study is to see if giving pramlintide and insulin before a meal would lower high blood sugar and if a glucagon (a naturally made hormone in the body but reduced in diabetes and its role is in prevention of low blood sugar) shot given in the late "after meal" time would prevent low blood sugar. The studies outlined in this proposal might help in developing new treatment options to target "after meal" high blood sugar and before meal low blood sugar in children. This would possibly help improve overall blood sugar control and prevent the long-term complications of diabetes.
Interventions
- DRUG Pramlintide and glucagon
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2002-07 |
| Est. Completion | 2005-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00206258
The ClinicalTrials.gov registry entry for NCT00206258 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pramlintide and glucagon is the first listed.
NCT00206258 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00206258 about?
NCT00206258 is a clinical study titled "The Role of Amylin and Glucagon in T1DM". The purpose of this study is to see if giving pramlintide and insulin before a meal would lower high blood sugar and if a glucagon (a naturally made hormone in the body but reduced in diabetes and its role is in prevention of low blood sugar) shot given in the late "after meal" time would prevent lo...
What is the current status of trial NCT00206258?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 2002-07. Estimated completion is 2005-08.
What interventions are being tested in trial NCT00206258?
The interventions under investigation include: Pramlintide and glucagon (DRUG).
Who is sponsoring clinical trial NCT00206258?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.